The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 23, 2023

Filed:

Apr. 09, 2020
Applicant:

Lonza Walkersville, Inc., Walkersville, MD (US);

Inventors:

Eytan Abraham, Potomac, MD (US);

Thomas Payne, Cambridge, GB;

Robert J. Young, London, GB;

Inbar Friedrich Ben Nun, Rockville, MD (US);

Assignee:

LONZA WALKERSVILLE, INC., Walkersville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/85 (2006.01); C12N 5/074 (2010.01); A61K 35/15 (2015.01); A61K 35/33 (2015.01); A61K 35/51 (2015.01); G01N 33/50 (2006.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C12N 15/85 (2013.01); A61K 35/12 (2013.01); A61K 35/15 (2013.01); A61K 35/33 (2013.01); A61K 35/51 (2013.01); C12N 5/0696 (2013.01); G01N 33/5073 (2013.01); C12N 2501/40 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2501/608 (2013.01); C12N 2506/11 (2013.01); C12N 2510/00 (2013.01);
Abstract

The current disclosure provides methods for reprogramming mammalian somatic cells by regulating the expression of endogenous cellular genes. Cellular reprogramming of somatic cells can be induced by activating the transcription of embryonic stem cell-associated genes (e.g., oct3/4) and suppressing the transcription of somatic cell-specific and/or cell death-associated genes. The endogenous transcription machinery can be modulated using synthetic transcription factors (activators and suppressors), to allow for faster, and more efficient nuclear reprogramming under conditions amenable for clinical and commercial applications. The current disclosure further provides cells obtained from such methods, along with therapeutic methods for using such cells for the treatment of diseases amendable to stem cell therapy, as well as kits for such uses.


Find Patent Forward Citations

Loading…